miR Scientific is proud to announce the commercial availability of the miR Sentinel™ Prostate Cancer Test

News provided by

miR Scientific, LLC

13 Jul, 2022, 19:00 IDT

NEW YORK, July 13, 2022 /PRNewswire/ -- miR Scientific, LLC announces the miR Sentinel™ Prostate Cancer Test is now commercially available in the United States, Puerto Rico and select international markets.  miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men >45 years of age at risk for prostate cancer.

The results of a recent clinical study performed at multiple sites within the US and Puerto Rico were presented at the 2022 American Urological Association's Annual Meeting.  In the study cohort of ~1100 men, the miR Sentinel™ Test was shown to identify molecular evidence of prostate cancer in at-risk men with 98.5% sensitivity and distinguish clinically non-significant (nominally No Pathological Evidence of Prostate Cancer and Grade Group 1), from clinically significant prostate cancer (nominally Grade Groups 2-5) with a prognostic sensitivity of 83% 2. 

"We believe that the miR Sentinel Test offers patients and providers a non-invasive means of accurately assessing a man's prostate cancer risk, which could potentially reduce unnecessary biopsies and biopsy-related complications in men with low-risk of clinically significant prostate cancer, while prioritizing diagnostic and treatment resources to those men that potentially harbor clinically significant prostate cancer," said Sam Salman, Chairman and CEO of miR Scientific.  "This aligns with miR Scientific's vision to revolutionize prostate cancer disease management by improving accessibility and accuracy of the tools used to assess each man's personal risk of aggressive disease."

In a subset analysis of men from this cohort where the findings of TRUS and MRI-guided biopsies disagreed on the presence of prostate cancer, the miR Sentinel™ Test was able to correctly identify 99% (71/72) of men found positive by either biopsy type while identifying all but 4 of 234 cases where prostate cancer was found by either TRUS or MRI resulting in a false negative rate of 1.7%. Additionally, 87% of men with PSA levels <3 found to have pathologic grade group 2 through 5 upon biopsy were identified by the miR Sentinel™ Test as having molecular evidence of intermediate or high risk of aggressive disease2. These findings suggest that the miR Sentinel™ Test may represent a significant improvement over the current standards of care and other tools being used to detect and classify prostate cancer.  

"Accurate assessment of a man's individual risk related to prostate cancer is one of the cornerstones of appropriate patient management.  The miR Sentinel Test has the potential to provide a significant improvement over the current tools that are available to physicians," said Laurence Klotz, MD, FRCSC, CM, miR Scientific's Chief Medical Officer, Professor of Surgery and Chair of Prostate Cancer Research, University of Toronto Sunnybrook.  "The implementation of such an innovation into practice could have a dramatic impact on outcomes through appropriately guiding the need for further diagnostic workup in men with elevated risk of significant cancer and guiding treatment in those subsequently diagnosed."

The current version of the miR Sentinel™ Test represents a refined and clinically validated assessment developed for commercialization based on our comprehensive miR Sentinel™ PCC4 assay, which received FDA Breakthrough Device Designation in third quarter 2020 and the original three-test proof of concept, published in the Journal of Urology1 in September 2020.

Additional information on the miR Sentinel™ Prostate Cancer Test as well as information on how to access the test can be found by visiting miRSentinel.com or calling 855-55CALLMIR from the United States or +1 (855) 552-2556.

About miR Scientific:  miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management Platform®, a proprietary, non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform powers the miR Sentinel™ Prostate Cancer Test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on the interrogation of small-non-coding RNAs extracted from urinary exosomes.

Contact: [email protected] 

Citations:

  1. Wang WW, Sorokin I, Akeksic I et al. Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. J Urol. (3); 466-475.
  2. Klotz L, Wang W, Pujals AL et al. A urinary exosome assay interrogating small non-coding RNAs accurately identifies and classifies prostate cancer into low-, intermediate-, or high-risk disease.  Abstract PDA-11-11; 2022 AUA Annual Meeting.